Today, we announced the completion of our End-of-Phase 2 meeting with the U.S. FDA and agreement on the design of a Phase 3 registrational program for #pemvidutide in the treatment of #obesity. Learn more in the full release: ir.altimmune.com/news-releases/…

We are thrilled to announce the appointment of Greg Weaver as CFO! Mr. Weaver’s experience in capital market transactions, investments, product launches and M&A will be an asset to our team as we advance innovative therapies for #metabolic diseases: bit.ly/4hHvfvI

Today, we provided a corporate update and published our third quarter 2024 financial results. Learn more about our recent business highlights in the full release: ir.altimmune.com/news-releases/… $ALT

We’re proud to sponsor this year’s MetALD Conference exploring the opportunities & challenges in #clinical drug development as we continue to advance innovative therapeutics for patients with #metabolic dysfunction-associated liver diseases: bit.ly/3CboUsn

Today, we presented new data from our 12-week Phase 1b trial of #pemvidutide in metabolic dysfunction-associated steatotic liver disease (#MASLD) at AASLD' The Liver Meeting®. Learn more: ir.altimmune.com/news-releases/…. #TLM24 #pemvidutide

Next week, members of our executive team will be participating in #firesidechats at the Evercore ISI and Piper Sandler Healthcare Conferences. Read the press release below for additional details, and connect with us onsite for 1x1 meetings: ir.altimmune.com/news-releases/….

This week, our CMO, Dr. Scott Harris will present body composition data from the Phase 2 MOMENTUM trial of #pemvidutide for #obesity and join a panel discussion at the SCWD Regulatory & Trials Update Workshop. Learn more: bit.ly/4eWw69w. #SCWD2024

#ICYMI Our CEO, Dr. Vipin Garg, joined CNBC’s “Fast Money” to share Altimmune’s progress, vision and future developments surrounding our lead candidate #pemvidutide, a #GLP1/#Glucagon dual receptor agonist for the treatment of #obesity and MASH. bit.ly/4fhfz05

Tomorrow, our CMO Dr. Scott Harris will be on a panel at #CVCT2024 in Washington, D.C. exploring the latest results from anti-obesity #clinicaltrials and their cardiovascular implications for patient care and future research. Learn more: bit.ly/4f4lHIM. CVCT - CardioVascular Clinical Trialists

Headed to #JPM25? Connect with us to learn more about #pemvidutide, our #GLP1/#glucagon dual receptor agonist for #obesity and #MASH. We’re eager to engage with industry leaders who share our commitment to innovation and patient impact! J.P. Morgan

Today, we announced the appointments of Jerry Durso and Teri Lawver to our Board of Directors. Their diverse backgrounds and multi-disciplinary expertise will help further the execution of our strategic vision as we bring pemvidutide to patients in need: ir.altimmune.com/news-releases/….

Today, we published our fourth quarter & full year 2024 financial results. Learn more about our recent business highlights and our upcoming virtual R&D Day: ir.altimmune.com/news-releases/…. Tune in to our webcast today at 8:30 a.m. ET: bit.ly/4gUPYL6

Today we hosted our virtual R&D Day where we shared updates and future development plans for #pemvidutide, our GLP-1/glucagon dual receptor agonist for #MASH as well as AUD and ALD. Watch the full replay here: investorday.altimmune.com

This week at #EASL2025, we’ll be presenting new analyses focused on the use of the #MASH Resolution Index (MASHResInd) algorithm to predict MASH resolution, developed by Dr. Rohit Loomba, on biopsy in patients treated with pemvidutide. Learn more here: ir.altimmune.com/news-releases/…

Today, we published our first quarter 2025 financial results. Learn more about our recent business highlights here: ir.altimmune.com/news-releases/…

Members of our executive team will be participating in fireside chats at upcoming #investor conferences taking place in New York, NY - connect with us for 1x1 meetings at the H.C. Wainwright & Co. BioConnect Conference & Jefferies Global Healthcare Conference! ir.altimmune.com/news-releases/…

We announced the initiation of our RECLAIM Ph2 trial to evaluate the efficacy & safety of #pemvidutide in patients with #AlcoholUseDisorder. Learn about the study here: ir.altimmune.com/investors/pres…

We’re looking forward to our presentations at #ADASciSessions! Tune in to learn more about pemvidutide, our GLP-1/glucagon dual receptor agonist in development for the treatment of #MASH, #obesity, alcohol use disorder & alcohol-associated liver disease: bit.ly/3HGE4IM

We’re proud to unveil positive topline results from our Ph2b IMPACT trial in #MASH, which position pemvidutide as the first product candidate to demonstrate significant MASH effects + #weightloss at just 24 weeks. Learn more here ir.altimmune.com/news-releases/…

We’ve enrolled the first patient in our RESTORE Phase 2 trial evaluating the efficacy and safety of #pemvidutide in subjects with Alcohol-Associated Liver Disease (#ALD). Learn more about the trial here: ir.altimmune.com/news-releases/…